Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2022)
22 slides from Vita Life Sciences's shareholder meeting presentation, May 11, 2022
Slide 1: Annual General Meeting
Annual General Meeting 11 May 2022
Slide 2: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2022
Slide 3: Henry Townsing, Chairman
Henry Townsing Chairman Mr Townsing brings over 30 years’ experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011. Mr Townsing was appointed as the Chairman of the Company effective 28t
Slide 4: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2022
Slide 5: Andrew O'Keefe, Managing Director
Andrew O’Keefe Managing Director Mr O’Keefe was appointed Managing Director on 1st January 2017. Mr O’Keefe has over 20 years’ experience within the Australian pharmaceutical and healthcare industry. During his career Mr O’Keefe has held senior leadership positions in publicly listed companies and w
Slide 6: Thank you
Thank you ANNUAL GENERAL MEETING 2022
Slide 7: Meeting Consumer Demand
Meeting Consumer Demand Distribution - Across several markets; Australia, Malaysia, Singapore, China, Vietnam, Thailand, and Indonesia Brands – Herbs of Gold, VitaHealth & VitaScience brands Products – 750 registered products across all markets Strong consumer demand – The Group meets increased dema
Slide 8: Strong Financial Performance
Strong Financial Performance Record Sales Pre-Tax Profit Balance sheet equity Dividend payment $57.1m, up 23% $11.2m, up 38% $30.4m, net cash $15.9m 5.75 cents/share, (without any borrowings) up 35% ANNUAL GENERAL MEETING 2022
Slide 9: Geographical Performance
Geographical Performance Australia is the single largest market with an increase of 45% to 53% in market share. 2021 revenue by geography Other Asia 4% $2M Australia 53% Singapore 10% $5.6M $30.3M Asia Total 47% revenue $57.1m Malaysia 34% $19.2M ANNUAL GENERAL MEETING 2022
Slide 10: Strategic priorities
Strategic priorities Our pillars BRAND BUILDING EDUCATION & INNOVATION TALENT WELLBEING OPERATIONAL LEVERAGE Key initiatives to support our pillars OVER 1000 RECRUITMENT OF NEW BUSINESS MODEL NEW ERP SYSTEM INCREASED BRANDING PHARMACIES RANGING NATIONAL TRAINING 30 NEW PRODUCTS IN THAILAND & & MARKE
Slide 11: Outlook
Outlook • The Group continues to be very well positioned to leverage market opportunities across the region. • The plans and vision for the business are strong and robust to drive future growth. • First half guidance will be provided early June. ANNUAL GENERAL MEETING 2022
Slide 12: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2022
Slide 13: Ordinary Resolutions
Ordinary Resolutions 1. Remuneration Report 2. Re-election of Director – Shane Teoh 3. Re-election of Director- Henry Townsing 4. Share buy back 5. Long Term Incentive Plan Shares-Managing Director 6. Long Term Incentive Plan Shares-Director ANNUAL GENERAL MEETING 2022
Slide 14: Proxy-Resolution 1
Proxy-Resolution 1 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1) Adoption of the Remuneration Report 25,502,045 43,100 0 11,220,054 ANNUAL GENERAL MEETING 2022
Slide 15: Proxy-Resolution 2
Proxy-Resolution 2 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 2) (Shane Teoh) 38,153,410 21,915 0 0 ANNUAL GENERAL MEETING 2022
Slide 16: Proxy-Resolution 3
Proxy-Resolution 3 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 3) (Henry Townsing) 37,429,676 66,915 0 0 ANNUAL GENERAL MEETING 2022
Slide 17: Proxy-Resolution 4
Proxy-Resolution 4 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 4) Share buy-back 38,127,790 50,344 0 0 ANNUAL GENERAL MEETING 2022
Slide 18: Proxy-Resolution 5
Proxy-Resolution 5 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Long Term Investment Plan Shares- 5) Managing Director 25,426,542 164,047 0 11,077,054 ANNUAL GENERAL MEETING 2022
Slide 19: Proxy-Resolution 6
Proxy-Resolution 6 PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Long Term Investment Plan Shares- 6) Director 25,350,385 240,204 0 10,394,446 ANNUAL GENERAL MEETING 2022
Slide 20: Proxy
Proxy PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1) Adoption of the Remuneration Report 25,502,045 43,100 0 11,220,054 Re-election of Director 2) 38,153,410 21,915 0 0 (Shane Teoh) Re-election of Director 3) (Henry Townsing) 37,429,676 66,915 0 0 4) Share buy-back 38,127,790 50,344 0
Slide 21: AGM Agenda
AGM Agenda 1. CHAIRMAN’S WELCOME ADDRESS 2. MANAGING DIRECTOR’S REVIEW 3. ORDINARY RESOLUTIONS 4. QUESTIONS & ANSWERS ANNUAL GENERAL MEETING 2022
Slide 22: Disclaimer
Disclaimer ANNUAL GENERAL MEETING 2022